MRKMerck Sharp & Dohme LLCFinished
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Melanoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 1/2
- Patients
- 146 (final count)
- Started
- Jun 26, 2020
- Main results expected
- Sep 24, 2025
- Fully finished
- Sep 24, 2025
- Results posted
- Aug 27, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Who Experienced an Adverse Event (AE)
Measured over: Up to approximately 17 months
Percentage of Participants Who Discontinued Study Intervention Due to an AE
Measured over: Up to approximately 13 months
Pathological Complete Response (pCR) Rate With 90% Confidence Interval (CI)
Measured over: Up to approximately 6 weeks
pCR Rate With 95% CI
Measured over: Up to approximately 6 weeks
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04303169 · record last updated 2026-08-27 · checked 2026-11-09 15:47 UTC